BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
BlossomHill Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 18, 2026
$14.16+0.22 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $38.43M
- P/E (TTM)
- –
- Dividend yield
- –
BlossomHill Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BlossomHill Therapeutics | Industry median |
|---|---|---|
| Market Cap | $36.09M | $166.30M |
| Enterprise Value | -$59.29M | $88.19M |
Balance sheet
| Measure | BlossomHill Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $95.38M | $61.43M |
| Net Cash (Debt) | $95.38M | $15.35M |
| Net Cash Per Share | $37.42 | $0.66 |
| Equity (Book Value) | -$174.78M | $49.09M |
| Book Value Per Share | -$68.58 | $1.37 |
| Tangible Book Value | -$174.78M | $23.52M |
| Working Capital | $82.35M | $76.81M |
Financial position
| Measure | BlossomHill Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 5.42 | 3.34 |
| Quick Ratio | 5.12 | 2.44 |
Shares
| Measure | BlossomHill Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 2,548,660 | 58,127,000 |
Scores
| Measure | BlossomHill Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.72 | -0.22 |
Calculated by StockData from BlossomHill Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.